How to Resolve Inconsistencies in Quality System Certificates for Overseas Registration of Imaging Devices

Key Summary

When registering imaging devices overseas, inconsistencies in quality system evidence are common. These typically appear as mismatches between NMPA, CE, FDA, ISO 13485, or MDSAP certificates and target country requirements, or as differences in quality system documentation submitted to different markets. Companies should first assess whether the target country regulates the product as a medical device, then determine the risk classification and registration pathway, and evaluate whether existing system evidence can be reused. The critical point is not simply translating old certificates, but building a consistent quality system evidence chain that includes system scope, product categories, audit reports, evidence of nonconformity closure, and change control records. If the target country requires a local agent or authorized representative, that party should confirm the applicability of quality system documents, while ensuring clear control of certificates, updates, and change processes. Common risks include expired certificates, certification scope not covering the product, version confusion in system documents, and lack of post-market surveillance provisions. Companies should prioritize organizing core quality system documents that are common across multiple countries, then perform localized conversion according to local regulations, and prepare gap declarations or supplementary audits in advance for differences.

For Chinese medical device companies, a prudent approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused. Registration in a target market usually simultaneously affects technical documentation, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance. If the project is driven only by a 'what documents to submit' mindset, it is prone to corrections or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies plan this issue within the framework of GHWP member countries and multi-country market access strategies, using one set of reusable core technical documents to support localization in different markets, rather than redoing documents temporarily for each country.

This article is compiled based on AIMEILI registration practice database, medical device international registration knowledge base, and publicly available regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authorities and the product documentation baseline.

Applicable Scenarios and Core Issues

Inconsistencies in quality system evidence for overseas registration of imaging devices often emerge during multi-country submission. A company may hold ISO 13485 certificates, CE marking files, FDA establishment registrations, or MDSAP certificates, yet the target country's registration authority still raises deficiencies, asserting that the quality system evidence is insufficient or mismatched.

The core issue is not 'whether a certificate exists,' but 'whether the certificate proves that the product continuously complies with local requirements in production, design, risk management, post-market surveillance, and other aspects.' For example, a company might directly submit domestic NMPA system documents to a Southeast Asian country, but the local requirement is that the system covers the entire product lifecycle and clearly identifies the correspondence between the quality system audit report and the registration certificate holder.

This situation is common in GHWP member countries, the Middle East, Latin America, and other emerging markets. Local regulations may draw on international frameworks, but implementation details differ, leading to inconsistencies in system documents, audit conclusions, and terminology definitions.

Companies need to first determine whether they are in such an applicable scenario, avoiding repeated corrective actions in the wrong direction.

Registration Decision Logic

First, determine whether the target country regulates the imaging device as a medical device or in vitro diagnostic device. Some countries regulate certain imaging equipment as radiation equipment or electrical equipment, in which case quality system requirements may differ.

Second, confirm the product risk classification and corresponding registration pathway. Different classifications require different levels of depth in system evidence review. Class II or Class III devices often require on-site audits or system inspection reports, while Class I devices may accept a self-declaration.

Third, evaluate whether existing certificates and audit reports such as NMPA, CE, FDA, ISO 13485, and MDSAP can be reused. If the target country recognizes MDSAP, the MDSAP audit report can serve as important evidence; if only a national system inspection is accepted, local audit arrangements must be made.

Fourth, clarify the applicant entity and certificate control. If the overseas manufacturer holds the certificate, the local agent usually communicates with the regulatory authority, but the quality system responsibility remains with the manufacturer; if the local representative is the registration certificate holder, the correspondence between system documents and the certificate holder must be confirmed.

Fifth, identify differences between existing quality system evidence and requirements in technical documentation, performance verification, risk management, clinical evaluation, labels and instructions, and post-market maintenance requirements, creating a gap list.

Documentation and Evidence

When quality system evidence is inconsistent, companies should focus on preparing the following materials.

• Quality system certificates: ISO 13485, MDSAP, CE certificate, FDA establishment registration, etc. Check that certificates are within validity and that the certification scope covers the imaging device.
• System document list: Quality manual, procedures, work instructions with version numbers and distribution records, proving that the submitted version matches the currently effective version.
• Audit reports and nonconformity records: Most recent audit report, evidence of nonconformity closure, and verification records of corrective action effectiveness.
• Evidence linking product and system: Design input/output records, risk management files, verification and validation reports, demonstrating that the product falls within the system scope.
• Label and instruction consistency documents: Target language versions, instruction revision history, and the correspondence between label changes and system change control records.
• Local agent declaration or authorization documents: Clarifying the agent's role in quality system oversight, and communication procedures for certificates, changes, and adverse event reporting.
• Post-market surveillance procedures: Complaint handling, vigilance system, annual updates or renewal arrangements, proving the system remains effective during subsequent maintenance.

Common Mistakes

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating and submitting domestic NMPA documents without rearranging evidence according to the target market pathway.
• Having too many model variations but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent only as a sales partner without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistencies among labels, instructions, promotional materials, and registration documents, leading to corrections or post-market compliance risks.
• Failing to plan multi-country document reuse, resulting in duplicated effort, increased cost, and longer timelines for each country.

Company Preparation Checklist

• Establish a comparison table between target country regulatory requirements and existing quality system, item by item.
• Confirm certificates are valid and that the certification scope covers all models of the imaging device.
• Obtain the most recent audit report and evidence of nonconformity closure in advance.
• Organize risk management documents, clinical evaluations, or performance verification data as annexes to system evidence.
• Designate a person or local agent to confirm language, units of measure, warning symbols, and other label requirements.
• Develop a change control process to ensure any post-registration system changes can be traced by the target country's regulatory authority.
• Plan the multi-country registration timeline, arranging on-site audits or document reviews appropriately.

AIMEILI Perspective

The most common misjudgment is believing that holding an ISO 13485 certificate automatically satisfies overseas registration system requirements. In reality, target country regulators are more concerned about whether the system evidence aligns with the specific product and the specific registration application, not just a valid certificate.

In the early phase of a project, a gap analysis should be conducted. Spend about two weeks comparing target country regulations, application document checklists, existing system certificates, and audit records side-by-side, avoiding blind translation and submission.

Reusable documentation includes ISO 13485 or MDSAP audit reports, general risk management documents, and stable design development validation records. What must be localized are labels and instructions, local agent documents, and country-specific quality system declarations or checklists.

The local agent is not a simple document transmitter. Companies must clarify with the agent the control of certificates, ensuring that all changes, renewals, and adverse event reports are jointly confirmed by the certificate holder and the agent, to avoid invalidation of the registration due to agent changes.

For multi-country registration, establish a structure of 'one core system, multi-country gap packages.' Common documents serve as the base, and each country only prepares differential supplements. This significantly reduces repeated sorting and correction risks.

Frequently Asked Questions

Will inconsistent quality system evidence lead to direct rejection?

In most cases, the regulatory authority will issue a deficiency notice requiring clarification or supplementary system evidence within a limited timeframe. If the deficiency is severe, such as an expired certificate or mismatched scope, the registration application may be directly rejected.

Can ISO 13485 and MDSAP substitute each other?

Some countries accept MDSAP as evidence of system audits, but this does not automatically substitute for an ISO 13485 certificate. Companies should confirm whether the target country explicitly recognizes MDSAP in its national regulations, and pay attention to the MDSAP auditing organization information and scope.

Can a local agent help resolve inconsistent quality system evidence?

A local agent can assist in communicating with the regulator and transmitting supplementary documents, but cannot replace the manufacturer's quality system responsibility. The company must still provide genuine and effective system evidence; the agent can help explain local regulatory expectations.

Quality System and Evidence Consistency

From the registration review perspective, quality system documentation is not an isolated certificate. Regulators typically focus on consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical documents. If the ISO 13485 certificate scope does not match the declared product, or production address, model specifications, instruction versions, and test reports are inconsistent, even if a company has prepared a large number of documents, supplementary explanations may be requested.

Companies should establish an evidence consistency checklist before submission, matching product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instruction version, and quality system certificate item by item. This seemingly basic step can significantly reduce the probability of deficiencies, especially for projects simultaneously submitted in multiple GHWP member countries or for multiple product lines.

Localization and Agent Responsibilities

Target market registration projects typically involve arrangements for local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for document submission, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies already holding CE, FDA, NMPA, or other market documentation, the focus of localization is converting reusable evidence into an acceptable submission structure for the target country, rather than rewriting a completely isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies must also maintain certificate validity, change records, dealer authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest significant effort during the certification phase but neglect post-market maintenance. Later, when production address changes, model expansion, instruction updates, or agent changes occur, misalignment between certificates and market sales often arises.

AIMEILI recommends incorporating this issue into the annual international registration plan: first clarify target market priorities, then establish a reusable documentation package and national gap list, and finally arrange submission, deficiency responses, post-market maintenance, and renewal milestones. The value of this approach is not only improving single-country registration efficiency, but more importantly, enabling companies to build a replicable overseas compliance capability, reducing the cost of starting from scratch for each new market.